ストックスクリーナーアプリを入手
97.50
3.72%
3.50
前日終値:
$94.00
開ける：
$92.89
24時間の取引高:
1.29M
Relative Volume:
1.18
時価総額：
$4.51B
収益：
-
当期純損益:
$-63.78M
株価収益率:
-36.38
EPS:
-2.68
ネットキャッシュフロー:
$-53.91M
1週間 パフォーマンス:
+5.20%
1か月 パフォーマンス:
+48.85%
6か月 パフォーマンス:
+819.81%
1年 パフォーマンス:
+665.91%
1日の値動き範囲:
$92.10
$101.03
1週間の範囲:
$86.56
$101.03
52週間の値動き範囲:
$7.575
$101.03
Celcuity Inc Stock (CELC) Company Profile
CELC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
97.50 | 4.35B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 開始されました | Guggenheim | Buy |
| 2025-07-01 | 再開されました | Stifel | Buy |
| 2024-07-22 | 開始されました | Leerink Partners | Outperform |
| 2024-02-22 | 開始されました | Stifel | Buy |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-08 | 開始されました | Canaccord Genuity | Buy |
| 2021-09-07 | 開始されました | Jefferies | Buy |
| 2021-07-29 | 開始されました | Cowen | Outperform |
| 2021-07-27 | 開始されました | Needham | Buy |
| 2021-01-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-11 | 再開されました | Craig Hallum | Buy |
| 2018-11-20 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Celcuity Inc (CELC) 最新ニュース
Celcuity Director Unloads Shares in a Major Stock Sale! - TipRanks
Celcuity Insider Sold Shares Worth $377,255, According to a Recent SEC Filing - MarketScreener
Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer TherapyHas The Bull Case Changed? - simplywall.st
Why Celcuity Inc. stock is popular among millennials2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Celcuity stock reaches all-time high of 96.56 USD By Investing.com - Investing.com Canada
How institutional buying supports Celcuity Inc. stock2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stock2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Price action breakdown for Celcuity Inc.July 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Key resistance and support levels for Celcuity Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited ReviewWhat's Changed - Yahoo Finance
When is the best time to exit Celcuity Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Wolfe Research Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - Nasdaq
How to track smart money flows in Celcuity Inc.July 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating By Investing.com - Investing.com South Africa
Celcuity (CELC) Price Target Increased by 16.06% to 97.66 - MSN
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Celcuity initiated with an Outperform at Wolfe Research - TipRanks
Wolfe Research initiates coverage on Celcuity stock with Outperform rating - Investing.com India
Celcuity submits gedatolisib new drug application to the FDA - TipRanks
Celcuity Submits NDA for Gedatolisib to FDA - TipRanks
Celcuity Inc Submits NDA for Gedatolisib to FDA - TradingView
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer - MarketScreener
Celcuity Inc. Submits New Drug Application for Gedatolisib to Treat Advanced Breast Cancer - Quiver Quantitative
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - The Manila Times
Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan
Celcuity Shares Fall After HC Wainwright Downgrade - MarketScreener
Celcuity dips as H.C. Wainwright downgrades to 'neutral' - TradingView
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy ApplicationCelcuity (NASDAQ:CELC) - Benzinga
HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77 - MarketScreener
HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94 - MarketScreener
Liquidity Mapping Around (CELC) Price Events - news.stocktradersdaily.com
Celcuity price target raised to $115 from $68 at Stifel - MSN
What analysts say about Celcuity Inc stockSell Signals and Alerts & Free Unlock Stock Analysis - earlytimes.in
Celcuity Stock Surges on Positive Phase 3 Results and Analyst Upgrades - timothysykes.com
Celcuity Inc. Earnings Call: Strong Progress Amid Challenges - The Globe and Mail
Celcuity Stock Surges as Analysts Raise Price Targets Following Positive Drug Trials - StocksToTrade
Celcuity Stock Surges on Positive Phase 3 Results for Breast Cancer Drug - StocksToTrade
Celcuity Stock Soars on Positive Phase 3 Trial Data for Gedatolisib - timothysykes.com
Celcuity’s Stock Soars with Promising Phase 3 Results - timothysykes.com
Is Celcuity (NASDAQ:CELC) Using Debt Sensibly? - 富途牛牛
Celcuity Shares Surge Amid Positive Developments - TipRanks
Celcuity Inc. (NASDAQ:CELC) Q3 2025 Earnings Call Transcript - Insider Monkey
Craig-Hallum Maintains Celcuity (CELC) Buy Recommendation - MSN
Sector ETF performance correlation with Celcuity Inc.July 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Stifel raises Celcuity stock price target to $115 on expanded trial potential - Investing.com Australia
Decoding Celcuity Inc (CELC): A Strategic SWOT Insight - GuruFocus
Celcuity price target raised to $108 from $96 at Craig-Hallum - MSN
Celcuity Inc (CELC) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):